Insights
Insights From Our Experts
Articles
Strategic PICO Planning: Enhancing Early-Phase Development for Market Access
Future-Proofing Early Development with Strategic PICO Planning A global pharmaceutical company with a diverse pipeline needed to align early clinical planning with future market access requirements—before Phase II. With Target Product Profiles (TPPs) still in development,…
How AI & Automation Plays a Role in Powering the Future of Compliant Pharma Marketing
In the pharmaceutical industry, marketing isn’t just about creativity—it’s about compliance. Every campaign must navigate a maze of Medical, Legal, and Regulatory (MLR) reviews, FDA guidelines, and therapeutic accuracy. The stakes are high, and the margin…
AI in DTP: Turning Data into Meaningful Care Moments
In today’s healthcare landscape, personalization isn’t a luxury—it’s a necessity. In his latest article for Med Ad News, Hari Ramachandran, Executive Vice President, Direct-to-Patient Product Management at EVERSANA, explores how Artificial Intelligence is transforming Direct-to-Patient (DTP)…
Reimagining Pharma Commercialization with AI Agents
A Q&A with Imtiaz Samjoo, EVERSANA, and Kevin Kallmes, Nested Knowledge. EVERSANA and Nested Knowledge have teamed up to revolutionize systematic literature reviews (SLRs) using AI. Their collaboration is streamlining workflows and unlocking faster, more precise…
A Deeper Dive into Pharmatizing AI & What It Will Mean to the Future of Commercialization
For the past 4 years, we have talked about our commitment to “Pharmatize AI” to deliver true change for the industry. The time to lead is now. We’re at a transformation moment where, through the power…
Reimagining Pharma Commercialization with AI Agents
AI isn’t just a tool—it’s a team member. That’s the bold vision that my colleague, Scott Snyder, Chief Digital Officer at EVERSANA, shared in a recent interview with pharmaphorum. Scott’s interview does a great job highlighting…
Unveiling the Real DTP: Beyond Common Misconceptions
Posted by
Hari Ramachandran on September 12, 20259/12/25
When most people hear “Direct-to-Patient” (DTP), they immediately think of a video call with a doctor—a telehealth visit. But in reality, DTP encompasses much more than just virtual consultations. DTP represents a strategic reorientation of existing…
Ready, Set, Simplify: PV Without the Hassle
Pharmacovigilance (PV) is a discipline layered with regulations, legacy systems, complex workflows, and global standards. Most PV platforms feel like they were built for experts, not users. Too often, PV systems become increasingly complex with every…
The Most-Favored-Nation Model: Global Benchmark or Global Risk?
In response to growing public concern over rising drug costs, U.S. policymakers have proposed a Most-Favored-Nation (MFN) pricing model, linking domestic drug prices to those negotiated in other developed countries, many of which operate under tightly…
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
The 340B program has struggled with implementing effective oversight of the covered entities since the program was established in 1992. Diversion and duplicate discounts are the primary issues that manufacturers face. Diversion typically happens when a…